Impaired coronary flow reserve in patients with non-ischemic heart failure;Disminución de la reserva de flujo coronario en pacientes con insuficiencia cardíaca no isquémica

Revista Espanola de Cardiologia

Volumn 56, Issue 4, 2003, Pages 354-360

  Coma Canella, Isabel ^a   García Velloso, María José ^a   Macías, Alfonso ^a   Villar, Luis ^a   Cosín Sales, Juan ^a   Martí Climent, Josep M ^a   Artaiz, Miguel ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

ATP; Coronary flow reserve; Heart failure; PET; Positron emission tomography

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMMONIA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NITROGEN 13;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART MUSCLE BLOOD FLOW; HUMAN; ISCHEMIC HEART DISEASE; MALE; POSITRON EMISSION TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE;

EID: 0037987844     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13045650     Document Type: Article

References (33)

1. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med 1994;330:1782-8.
2. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
3. Pitkanen OP, Nuutila P, Raitakari OT, Porkka K, Iida H, Nuotio I, et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998;47:248-54.
4. Gimelli A, Schneider-Eicke J, Neglia D, Sambuceti G, Giorgetti A, Bigalli G, et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy. J Am Coll Cardiol 1998;31:366-73.
5. Choudhury L, Elliott P, Rimoldi O, Ryan M, Lammertsma AA, Boyd H, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.
6. Drzezga AE, Blasini R, Ziegler SI, Bengel FM, Picker W, Schwaiger M, et al. Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl Med 2000;41:837-44.
7. Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. Circulation 1995;92:796-804.
8. Choudhury L, Rosen SD, Patel DP, Nihoyannopoulos P, Camici PG. Coronary flow reserve in primary and secondary left ventricular hypertrophy: a study with positron emission tomography. Eur Heart J 1997;18:108-16.
9. Knecht M, Burkhoff D, Yi GH, Popilskis S, Homma S, Packer M, et al. Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs. J Mol Cell Cardiol 1997;29:217-27.
10. Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 1996;26(Suppl 2):S9-12.
11. Dexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60.
12. Katz SD. The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Prog Cardiovasc Dis 1995;38:23-50.
13. Takeshita A, Hirooka Y, Imaizumi T. Role of endothelium in control of forearm blood flow in patients with heart failure. J Card Fail 1996;2:S209-15.
14. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, et al. Changes in plasma endothelin-1 levels refects clinical response to b-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
15. Camici PG. Positron emission tomography and myocardial imaging. Heart 2000;82:475-80.
16. Agustí Escasany A, Durán Dalmau M, Arnau de Bolós JM, Rodríguez Cumplido D, Diogène Fadini E, Casas Rodríguez J, et al. Tratamiento médico de la insuficiencia cardíaca basado en la evidencia. Rev Esp Cardiol 2001;54:715-34.
17. Muzik O, Beanlands R, Wolfe E, Schwaiger M. Automated region definition for cardiac nitrogen-13-ammonia PET imaging. J Nucl Med 1993;34:336-44.
18. Muzik O, Beanlands RSB, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
19. Shikama N, Himi T, Yoshida K, Nakao M, Fujiwara M, Tamura T, et al. Prognostic utility of myocardial blood flow assessed by N-13 ammonia positron emission tomography in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1999;84:434-9.
20. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J, et al. Effect of aging on myocardial perfusion reserve. J Nucl Med 1995;36:2032-6.
21. Czernin J, Muller P, Chan S, Brunken RC, Porenta G, Krivokapich J, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-9.
22. Merlet P, Mazoyer B, Hittinger L, Valette H, Saal JP, Bendriem B, et al. Assessment of coronary reserve in man: comparison between positron emission tomography with oxygen-15-labeled water and intracoronary Doppler technique. J Nucl Med 1993;34:1899-904.
23. Mathier MA, Rose GA, Fifer MA, Miyamoto MI, Dinsmore RE, Castano HH, et al. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1998;32:216-24.
24. Jeremias A, Filardo SD, Whitbourn RJ, Kernoff RS, Yeung AC, Fitzgerald PJ, et al. Effects of intravenous and intracoronary adenosine 5′-triphosphate as compared with adenosine on coronary flow and pressure dynamics. Circulation 2000;101:318-23.
25. Bravo N, Giménez M, Mejía S, García-Velloso MJ, Coma-Canella I. Prognostic value of myocardial perfusion imaging with adenosine triphosphate. J Nuclear Cardiol 2002;9:395-401.
26. De Mey JG, Vanhoutte PM. Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries. J Physiol (Lond) 1981;316:347-55.
27. Nitenberg A, Foult JM, Blanchet F, Zouioueche S. Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathy. Am J Cardiol 1985;55:748-54.
28. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.
29. Adamopoulos S, Parissis J, Kroupis C, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 2001;22:791-7.
30. Vidal B, Roig E, Pérez-Villa F, Orús J, Pérez J, Jiménez V, et al. Valor pronóstico de los niveles de citocinas y neurohormonas en la insuficiencia cardíaca severa. Rev Esp Cardiol 2002;55:481-6.
31. Herrera Garza EH, Herrera Garza JL, Rodríguez González H, Treviño A, Ibarra Flores M, Torre Amione G. Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002;55:61-6.
32. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997;80(Suppl):L41-5.
33. Ohlstein EH, Arleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 1998;30:167-73.